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Profiling of the metabolic 
transcriptome via single molecule 
molecular inversion probes
Tessa de Bitter1, Carlijn van de Water1, Corina van den Heuvel1, Carolien Zeelen1,  
Astrid Eijkelenboom1, Bastiaan Tops1, Egbert Oosterwijk2, Dimitar Kolev2, Peter Mulders2, 
Mark ter Laan3, Sanne van Lith1 & William Leenders1
Cancer-specific metabolic alterations are of high interest as therapeutic targets. These alterations vary 
between tumor types, and to employ metabolic targeting to its fullest potential there is a need for 
robust methods that identify candidate targetable metabolic pathways in individual cancers. Currently, 
such methods include 13C-tracing studies and mass spectrometry/ magnetic resonance spectroscopic 
imaging. Due to high cost and complexity, such studies are restricted to a research setting. We here 
present the validation of a novel technique of metabolic profiling, based on multiplex targeted next 
generation sequencing of RNA with single molecule molecular inversion probes (smMIPs), designed 
to measure activity of and mutations in genes that encode metabolic enzymes. We here profiled 
an isogenic pair of cell lines, differing in expression of the Von Hippel Lindau protein, an important 
regulator of hypoxia-inducible genes. We show that smMIP-profiling provides relevant information 
on active metabolic pathways. Because smMIP-based targeted RNAseq is cost-effective and can be 
applied in a medium high-throughput setting (200 samples can be profiled simultaneously in one next 
generation sequencing run) it is a highly interesting approach for profiling of the activity of genes of 
interest, including those regulating metabolism, in a routine patient care setting.
In the past four decades an overwhelming amount of data has become available on the molecular events that 
underlie carcinogenesis. Research has mainly focused on molecular alterations and their consequences for, among 
others, the PI3K/pAKT/mTOR pathway1–4 and cell cycle control, apoptosis5, 6 and DNA repair pathways7, 8. 
Currently, numerous FDA-approved drugs are available that target cancer cells based on these genetic defects 
with a level of specificity that is not attainable with conventional chemotherapies9, 10, permitting personalized 
medicine. Whereas targeted cancer therapies may prolong survival, it is now widely recognized that inherent 
genetic instability and tumor plasticity ultimately leads to therapy resistance of most cancers11–14.
Whatever the underlying oncogenic mutations, for proliferation cancer cells need to generate ATP to maintain 
energy balance and ion homeostasis, import carbon and nitrogen sources for synthesis of amino acids, nucleo-
tides and lipids15, 16 and maintain redox potential to protect cells against oxidative stress17. Blocking one or more 
of these processes with specific inhibitors may prohibit proliferation and/or sensitize cells to toxic therapy in a 
synthetic lethality approach18. As an example, increasing oxidative stress in a cancer with metabolic inhibitors 
(e.g. of enzymes that produce NADPH) may enhance the efficacy of radiotherapy19 or chemotherapy20. With the 
increasing knowledge of deranged metabolic pathways in cancer21–24 (adjuvant) targeting of cancer-specific met-
abolic pathways may be a highly interesting addition to current treatment protocols.
The best-known example of cancer-specific metabolic adaptation is aerobic glycolysis, also known as the 
Warburg effect25. Warburg tumors produce lactate from pyruvate, rather than shuttle pyruvate into the mito-
chondrial tricarboxylic acid (TCA) cycle. As glycolysis is inefficient in terms of ATP production, cancer cells 
characteristically upregulate expression of genes encoding glucose transporters GLUT1 and/or GLUT3, hex-
okinase 2, monocarboxylate transporters (to secrete lactate) and carbonic anhydrase-9 and -12 (to ensure pH 
homeostasis)26. Besides glucose, glutamine and fatty acids are recognized as important fuels for cancer cells that 
adjust expression of metabolic enzymes accordingly27–30.
1Dept of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands. 2Dept of Urology, Radboud 
University Medical Centre, Nijmegen, The Netherlands. 3Dept of Neurosurgery, Radboud University Medical Centre, 
Nijmegen, The Netherlands. Correspondence and requests for materials should be addressed to W.L. (email: William.
leenders@radboudumc.nl)
Received: 13 April 2017
Accepted: 18 August 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCieNTifiC RepoRts | 7: 11402  | DOI:10.1038/s41598-017-11035-0
While metabolic adaptations are mostly seen as a consequence of carcinogenesis, it has been unequivocally 
established that metabolic alterations can also cause cancer, examples being mutations in genes encoding suc-
cinate dehydrogenase (SDH, pheochromocytoma and paraganglioma), fumarate hydratase (FH, papillary renal 
cancers) and isocitrate dehydrogenase 1 and 2 (IDH1/2, among others acute myeloid leukemia and gliomas)31–37. 
Clear cell renal cell carcinoma (ccRCC) is also considered a metabolic cancer with metabolic alterations result-
ing from inactivating mutations in or epigenetic silencing of VHL found in ~80% of cases38, 39. pVHL is a major 
regulator of ubiquitination and breakdown of hypoxia inducible transcription factors HIF-1α and HIF-2α38. 
Mutations in the aforementioned metabolic enzymes and in VHL have been shown to induce epigenetic altera-
tions that affect expression of other metabolic enzymes in an unpredictable fashion40–43.
To apply inhibitors of metabolism as potential additions to the current anti-tumor armamentarium, it is of 
high importance to identify which metabolic pathways are active in a specific cancer in a personalized fashion. 
Here we applied a novel next generation-sequencing based method using single molecule molecular inversion 
probes (smMIPs)44, to detect expression levels of 104 genes involved in metabolism, and concomitantly iden-
tify variants therein. As a proof of concept, we applied smMIPs to map part of the metabolic transcriptome of 
a VHL-defective ccRCC cell line and a VHL-rescued isogenic derivative, as well as in four clinical samples of 
clear cell renal cell cancers, with matching normal kidney tissue, and patient-derived glioma xenograft models. 
We validated the technique by correlating results with whole transcriptome RNAseq data (as gold standard for 
transcriptome analysis) and protein expression. We further verified the ability of the assay to detect oncogenic 
mutations in cell lines and patient tumor tissues.
Our data show that targeted RNA sequencing of transcripts encoding metabolic enzymes using smMIPs pre-
dict the predominant metabolic pathways that are operational in cancer and simultaneously allows variant detec-
tion in the targeted transcripts.
Results
SmMIP based library preparation and sequencing. SmMIP-based next generation sequencing (NGS) 
of genomic DNA was recently introduced in routine diagnostics in our institute to detect tumor-associated muta-
tions in DNA45. To investigate whether smMIPs can also be used for multiplex determination of gene expression 
levels, concomitant with variant detection, we designed a smMIP set for targeted detection and sequencing of 104 
transcripts encoding metabolic enzymes (see Table 1) and 18 tyrosine kinases with relevance for oncology (not 
shown). The technique is summarized in Fig. 1, and consists of annealing of a panel of hundreds of specifically 
designed smMIPs to cDNAs of interest in a sample. SmMIPs are composed of a ligation and extension probe, 
connected by a backbone. After hybridization of an individual smMIP to its target cDNA via its specific ligation 
and extension probes, a gap of 112 nt is left which is then enzymatically filled and ligated, leaving a library of cir-
cularized smMIPs. After purification and PCR with barcoded primers in the smMIP backbone, the library is sub-
jected to next generation sequencing followed by bio-informatic analysis (see Materials and Methods for details).
To establish the strength of the technique we used the VHL-defective ccRCC cell line SKRC746 and its 
VHL-complemented variant SKRC7-VHLHA (expressing functional VHL with a haemagglutinin-tag) as a proto-
typical isogenic cell line pair with different metabolic characteristics: the lack of VHL in SKRC7 results in consti-
tutive stabilization of HIF-1α and HIF-2α and a pseudohypoxic response39, 46, 47. Re-introduction of VHL leads to 
restored HIF1/2 breakdown and normalized expression levels of hypoxia-induced genes.
Whole RNAseq-derived gene expression data of SKRC7 cells (used here as gold standard) confirmed the 
presence of a nonsense and functionally inactivating Q132-stop mutation in 100% of VHL transcripts (Fig. 2a) 
whereas only wtVHL transcripts were detected in the SKRC7VHLHA (Fig. 2b), and this was readily reproduced 
in the smMIP assay (Fig. 2c,d). Overexpression of VHL transcripts in SKRC7-VHLHA cells was observed both in 
whole RNAseq datasets (expressed as Transcript per Million, TPM) and in smMIP based datasets (expressed as 
Fragment per Million, FPM) (Fig. 2e). Overexpression was also seen on the VHL protein level (see western blot 
in Fig. 2f).
Optimization of library preparation. Using an initial set of 642 smMIPs, covering the 104 transcripts of 
interest for this study (see Table 1), we tested our protocol of library preparation with 50 ng of hexamer-primed 
cDNA on 13 different RNA samples (cell line -and xenograft derived) of which also whole RNAseq datasets were 
available. A 25-cycle PCR with barcoded primers on the circularized smMIP library yielded PCR fragments of 
the expected size of 266 bp (not shown). Illumina NextSeq sequencing of the libraries generated with RNA from 
SKRC7 and SKRC7-VHL cells, yielded 286,000 and 69,000 annotated unique reads respectively (corrected for 
PCR-amplicates based on the unique molecule identifier [UMI] sequence in the smMIP), which is in the range 
of other samples run with the same smMIP panel (not shown). For most transcripts, performance of individual 
smMIPs varied greatly, a known phenomenon also in DNA smMIP NGS45 (see example in Table 2, showing FPM 
values for 10 different smMIPs designed against the VHL transcript in both cell lines). This was a priori reason to 
include at least 5 smMIPs per gene transcript in our panel, allowing transcriptome analysis using mean FPM val-
ues for each transcript. This number was a trade-off between generating expensive, large panels which would yield 
in part futile and irrelevant data, and too small panels resulting in under- or overestimation of transcript levels.
First we compared the targeted smMIP RNAseq dataset to a whole transcriptome RNAseq dataset (con-
sidered as gold standard), performed on different RNA isolates from the same cell lines. The whole RNAseq 
dataset consisted of 3.2 × 107 and 3.4 × 107 reads, assigned to 44,503 different transcripts for SKRC7 and 
SKRC7-VHLHA, respectively. For each transcript of interest, TPM values from the whole RNAseq dataset were 
plotted against mean FPM values from smMIP analyses. When performed separately for metabolic transcripts 
and tyrosine kinase transcripts, these analyses gave correlation coefficients of 0.903 and 0.974, respectively, for 
SKRC7 (Fig. 3a,b) and 0.784 and 0.903, respectively, for SKRC7-VHLHA (Fig. 3c,d), suggesting that, as expected, 
expression of metabolic genes is subject to more biological variation than of tyrosine kinases. Plotting whole 
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Gene Symbol Gene name RefSeq mRNA ID (hg19)
ABAT (4-)Aminobutyrate transaminase NM_001127448.1
ACACA Acetyl-CoA carboxylase alpha NM_198834.2
ACACB Acetyl-CoA carboxylase beta NM_001093.3
ACLY ATP citrate lyase NM_001303275.1
ACO2 Acotinase 2 NM_001098.2
ACSS2 Acetyl-CoA synthetase NM_001242393.1
ALDOA Aldolase, fructose-bisphosphate A NM_000034.3
ARHGAP26 Rho GTPase activating protein 26 NM_015071.4
ATG4A Autophagy related 4 A, cysteine peptidase NM_052936.3
ATP5A1 ATP synthase complex, F1-ATP SYNTHASE SUBUNIT NM_001257335.1
ATP5C1 ATP synthase complex, F1-ATP SYNTHASE SUBUNIT NM_001001973.1
BCAT1 Branched chain amino-acid transaminase 1, cytosolic NM_001178094.1
BCAT2 Branched chain amino-acid transaminase 2, mitochondrial NM_001284325.1
C12orf5 (TIGAR) TP53-induced glycolysis regulatory phosphatase NM_020375.2
CA12 Carbonic anhydrase XII NM_206925.2
CA9 Carbonic anhydrase IX NM_001216.2
CBR1 Carbonyl reductase 1 NM_001286789.1
CBS Cystathione β-synthase NM_000071.2
CHKA Choline kinase alpha NM_212469.1
CKB Creatine kinase, braintype NM_001823.4
CPT1A Carnitine palmitoyltransferase NM_001031847.2
CS Citrate synthase NM_004077.2
CYCS Cytochrome C, somatic NM_018947.5
D2HGDH D-2-hydroxyglutarate dehydrogenase NM_152783.4
EGLN1 Prolylhydroxylase NM_022051.2
ENO1 Enolase 1, (alpha) NM_001428.3
EPAS1 Hypoxia-inducible factor 2-alpha NM_001430.4
FASN Fatty acid synthase NM_004104.4
FH Fumarate hydratase NM_000143.3
G6PC Glucose-6-phosphatase, catalytic subunit NM_000151.3
G6PD Glucose-6-phosphate dehydrogenase NM_000402.4
GAD1 Glutamate decarboxylase NM_000817.2
GAPDH Glyceraldehyde-3-phosphate dehydrogenase NM_002046.5
GCLC Glutamate cysteine ligase NM_001498.3
GCLM Glutamate cysteine ligase NM_001308253.1
GFPT1 Fructose-6-phosphate amido-transferase NM_001244710.1
GLDC Glycine dehydrogenase NM_000170.2
GLS Glutaminase NM_001256310.1
GLUD1 Glutamate dehydrogenase 1 NM_005271.3
GLUD2 Glutamate dehydrogenase 2 NM_012084.3
GLUL Glutamine synthetase NM_001033056.3
GOT1 Glutamate oxaloacetate transaminase NM_002079.2
GPI Glucose-6-phosphate isomerase NM_001289789.1
GPI Phosphoglucose isomerase = GPI NM_001289790.1
GPT Glutamate pyruvate transaminase NM_005309.2
GSS Glutathione synthetase NM_000178.2
HIF1A Hypoxia-inducible factor 1-alpha NM_001530.3
HK1 Hexokinase 1 NM_000188.2
HK2 Hexokinase 2 NM_000189.4
HK3 Hexokinase 3 NM_002115.2
IDH1 Isocitrate dehydrogenase 1 (NADP + ), soluble NM_005896.3
IDH2 Isocitrate dehydrogenase 2 (NADP + ), mitochondrial NM_002168.3
IDH3A Isocitrate dehydrogenase 3, mitochondrial, alpha NM_005530.2
IDH3B Isocitrate dehydrogenase 3, mitochondrial, beta NM_006899.3
IDH3G Isocitrate dehydrogenase 3, mitochondrial, gamma NM_174869.2
L2HGDH L-2-hydroxyglutarate dehydrogenase NM_024884.2
Continued
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transcriptome RNAseq data against unique reads obtained with the best performing smMIP per transcript, or 
the median of unique reads for each transcript (to prevent bias by non- or poor-performing smMIPs) did not 
improve this correlation (not shown).
One of the appealing characteristics of targeted RNAseq using smMIPs is that panels can be expanded to 
detect additional transcripts. To test how this affects the outcome of the assay, we added to our initial panel 222 
smMIPs for targeted detection and sequencing of other transcripts of interest and re-performed the assay using 
Gene Symbol Gene name RefSeq mRNA ID (hg19)
LDHA Lactate dehydrogenase A NM_001135239.1
LDHB Lactate dehydrogenase B NM_001174097.2
MAPK8 Mitogen-activated protein kinase 8 NM_001278547.1
MDH1 Malate dehydrogenase 1 NM_001199111.1
MDH2 Malate dehydrogenase 2 NM_001282403.1
MYC V-myc avian myelocytomatosis viral oncogene homolog NM_002467.4
NAMPT Nicotinamide phosphoribosyltransferase NM_005746.2
NAPRT1 Nicotinate phosphoribosyltransferase NM_145201.5
NOX1 NADPH oxidase 1 NM_007052.4
NOX3 NADPH oxidase 3 NM_015718.2
NOX4 NADPH oxidase 4 NM_016931.4
NQO1 NAD(P)H dehydrogenase, quinone 1 NM_000903.2
OGDH Oxoglutarate (alpha-ketoglutarate) dehydrogenase NM_001003941.2
PARP1 Poly (ADP-ribose) polymerase 1 NM_001618.3
PC Pyruvate carboxylase NM_000920.3
PDHA1 Pyruvate dehydrogenasealpha 1 NM_000284.3
PDK1 Pyruvate dehydrogenase kinase 1 NM_001278549.1
PFKFB1 Phosphofructokinase 2, PFKFB1 NM_001271805.1
PFKM Phosphofructokinase 1, PFKM NM_001166686.1
PGAM1 Phosphoglycerate mutase 1 NM_002629.3
PGD Phosphogluconate dehydrogenase NM_002631.3
PGK1 Phosphoglycerate kinase 1 NM_000291.3
PGK2 Phosphoglycerate kinase 2 NM_138733.4
PKM Pyruvate kinase, muscle NM_001206796.2
PRDX1 Peroxiredoxin 1 NM_001202431.1
PRKAA1 AMP-activated protein kinase, AMPK, catalytic subunit α1 NM_006251.5
PRKAA2 AMP-activated protein kinase, AMPK, catalytic subunit α2 NM_006252.3
RPIA Ribose 5-phosphate isomerase A NM_144563.2
SDHA Succinate dehydrogenase complex, subunit A NM_001294332.1
SDHB Succinate dehydrogenase complex subunit B NM_003000.2
SDHC Succinate dehydrogenase complex, subunit C NM_003001.3
SDHD Succinate dehydrogenase complex, subunit D NM_003002.3
SLC16A1 Monocarboxylate transporter 1 NM_001166496.1
SLC16A3 Monocarboxylate transporter 4 NM_001206952.1
SLC16A7 Monocarboxylate transporter 2 NM_001270622.1
SLC1A2 Glutamate transporter, high glial high affinity 2 NM_001195728.2
SLC25A5 Adenine nucleotide translocase 2 NM_001152.4
SLC2A1 Glucose transporter 1 NM_006516.2
SLC2A3 Glucose transporter 3 NM_006931.2
SLC5A1 Sodium glucose cotransporter NM_001256314.1
SLC7A1 Cationic amino acid transporter, y + system NM_003045.4
SLC9A1 Na+/H+ proton antiporter NM_003047.4
SOD1 Superoxide dismutase 1 NM_000454.4
SOD2 Superoxide dismutase 2, mitochondrial NM_000636.2
TALDO1 Transaldolase NM_006755.1
TP53I3 Tumor protein p53 inducible protein 3 NM_004881.4
TXN Thioredoxin NM_001244938.1
VHL Von Hippel Lindau NM_198156.2
Table 1. Metabolic transcripts for smMIP design.
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Figure 1. Principle of smMIP-based targeted RNA sequencing. The procedure depends on the hybridization of 
molecular inversion probes consisting of a ligation and an extension probe that are connected via a backbone. 
Capture hybridization leaves for each smMIP a gap of 112 nt that is enzymatically extended and closed by 
ligation. After exonuclease digestion of non-ligated probes, the remaining library of circularized smMIPS is 
PCR-amplified with primers in the smMIP backbone. Note that the ligation probe is flanked by a random 8N 
sequence that allows correction for PCR duplicates. During PCR, for each sample a unique barcode primer is 
used allowing identification of sample-specific reads.
Figure 2. (a,b) IGV representation of the VHL locus of SKRC7 and SKRC7-VHLHA cells. BAM files containing 
whole RNAseq data from these cell lines were loaded into IGV. Note the CAA-UAA mutation, resulting in 
the VHL Q132-stop mutation at the protein level. c and d show SeqNext representations of the same VHL locus 
of SKRC7 (c) and SKRC7-VHLHA cells (d). (e) bar graph showing VHL-related TPM and FPM values of 
SKRC7 and SKRC7-VHLHA. (f) Western blot of SKRC7 cells and the VHL-expressing derivative, stained with 
an anti-HA antibody and an antibody against GAPDH as control house keeping protein. Panel f represents 2 
cropped images from different western blots, loaded with the same protein samples, derived from SKRC7 and 
SKRC7-VHL cells as indicated. The corresponding full blots are presented in Supplementary Figure 2.
www.nature.com/scientificreports/
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newly isolated RNA from the same cell lines. Relative levels of transcripts within samples correlated well between 
assays with the initial and the expanded smMIP set (SKRC7: r = 0.903, SKRC7-VHLHA: r = 0.876).
Functional validation of targeted smMIP data. Having confirmed the validity of the smMIP dataset, 
we analyzed expression levels of genes involved in metabolism in SKRC7 and SKRC7-VHLHA cells. Figure 4a 
and b show two biological duplicates of smMIP-based mean FPM values for a number of transcripts involved 
in glycolysis. Expression of HIF target genes glucose transporter 1 and 3 (SLC2A1 and SCL2A3), monocarbox-
ylate transporter MCT4 (SLC16A3), carbonic anhydrases 9 and 12 (CA9, CA12), hexokinase 2 (HK2), lactate 
dehydrogenase A (LDH-A) and phosphoglycerate kinase (PGK1) were significantly and reproducibly reduced 
in SKRC7-VHLHA cells relative to SKRC7 cells (Fig. 4a,b), in line with data obtained from whole transcriptome 
RNA seq data (Fig. 4c). Relative expression levels of CA9 and HK2 transcript levels were further confirmed on 
the protein level (Fig. 4d). The strong reduction of CA9, HK2 and LDHA, all target genes of HIF, was in line with 
expectations.
smMIP SKRC7 SKRC7 + VHL
VHL_1 6.98 0.00
VHL_2 20.94 6293.31
VHL_3 0.00 115.74
VHL_4 317.58 54614.37
VHL_5 0.00 1504.61
VHL_6 55.84 14120.17
VHL_7 125.64 16680.89
VHL_8 27.92 0.00
VHL_9 6.98 1157.39
VHL_10 62.82 14.47
Table 2. variability in FPM values for different smMIPs designed to detect VHL.
Figure 3. smMIP-based targeted RNA sequencing correlates well with whole transcriptome RNAseq. Mean 
smMIP-based metabolic FPM levels (a,c) and tyrosine kinase transcript FPM levels (b,d) were plotted to TPM 
levels of the same transcripts, extracted from whole RNAseq data. Note that the transcripts with very low FPM 
values (10−2FPM) were not detected in the RNAseq dataset. We included these transcripts in these analyses 
although they may have lowered the Pearson coefficient.
www.nature.com/scientificreports/
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We next tested the assay on clinical renal cell cancers. Of four tumor nephrectomies we sampled normal 
kidney tissue and matched tumor for smMIP profiling. Striking and highly significant differences were found 
between normal kidney and tumor tissue, with high levels in tumor samples of transcripts of HIF target genes 
SLC2A1 (encoding Glucose transporter GLUT-1), monocarboxylate transporter SLC16A3 (MCT4), CA9, and 
LDHA, and low levels of LDHB in contrast to matched normal kidney (Fig. 4e). Furthermore, the assay readily 
detected a somatic stop mutation in VHL in renal cell cancer, but not in the corresponding normal kidney tissue 
(Table 3).
Variant detection. To investigate whether smMIP based RNAseq allows efficient detection of single nucle-
otide variants (SNVs), we performed variant calling of the smMIP library in SeqNext software. Several heterozy-
gous and homozygous variants were detected that could be validated in the whole RNAseq dataset (see VHL 
example in Fig. 2c and d). We then further validated the sensitivity of the assay to detect SNVs (called a variant in 
relation to reference genome hg19) and performed smMIP analysis on RNA, isolated from the IDH1R132H mutant 
oligodendroglioma line E47848 and the astrocytoma cell line E98, in which we previously identified a novel muta-
tion in IDH1 (IDH1R314C)35. Both mutations were identified (Fig. 5a,b). Finally, a patient glioma with a genetically 
confirmed IDH1R132H mutation was subjected to the assay. Again, the mutation was readily detected (Fig. 5c).
Figure 4. SmMIP-based targeted RNAseq reveals decreased expression levels in SKRC7-VHL cells of 
glycolysis related genes a.o. SLC2A1, CA9, HK2 and LDHA in two independent duplicate experiments (a,b). 
Relative values were comparable to those obtained from whole transcriptome RNAseq analysis (c), which is in 
agreement with the correlation shown in Fig. 3. Differences in expression levels were validated on the protein 
level for HK2 and CA9, using tubulin as house keeping control (Fig. 4d). Gene transcript levels of hypoxia 
inducible genes are very high in surgically obtained clear cell renal cell cancer samples, relative to peritumorally 
obtained normal kidney tissue (e, *p = 0.01; **p < 0.003, ***p < 0.0003, Students’ T-test) (Fig. 4e).
Gene Name
Nuc 
Change Coverage
AA 
Change Hint c. HGVS p. HGVS Weighting
Kidney VHL
Renal cancer VHL VHL CG (het)
9% (22) 
[9% (11) / 
9% (11)]
[STOP] 
AA 130 
(E2/48)
RF changed c.246_247delCG p.Val83Argfs*48 distinct
Table 3. Somatic mutation (frame shift resulting in a stop) in VHL in renal cell cancer, but not in peritimoral 
non-neoplastic tissue.
www.nature.com/scientificreports/
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Discussion
Currently, identifying metabolic pathways in tissues is only feasible in a research setting, inferring metabolic 
pathways from metabolite concentrations as detected with in vivo 1H-, 13C- or 31P-based magnetic resonance 
spectroscopic imaging28, 49 or mass spectrometry50–52. These techniques cannot be applied for routine patient 
diagnostics. Although profiling of the activity of metabolic genes cannot be considered as equivalent to metab-
olomic analysis or metabolic flux analysis, we here show that smMIP-based targeted RNA sequencing can be 
applied to any tissue and does yield reliable functional information, as demonstrated here by analysis of effects of 
VHL-reconstitution in ccRCC. We further present evidence that profiling of clinical renal cell cancer tissues as 
expected shows high levels of hypoxia-induced genes suggesting extensive glycolysis, while also unambiguously 
revealing the presence of VHL mutations, all in line with known biology of these cancers. Similarly, the assay 
unambiguously identifies the IDH1-R132H mutation in glioma, with 50% mutant/wild type reads, confirming 
heterozygosity for this mutation.
SmMIP-based RNA NGS has advantages over whole RNAseq. It yields workable data at a fraction of the 
cost of whole RNAseq, and smart positioning of extension and ligation target sequences allows the design of 
splice-variant-specific smMIPs. Furthermore, smMIP sets can be extended at any time with novel smMIPs of 
interest without affecting performance. Efficacy of different smMIPs that are designed to detect the same tran-
script is variable. As for now, it is difficult to discriminate between low intrinsic efficiency of a smMIP and low 
abundance of the target sequence (e.g. in case of pseudo-exons), and these issues should be resolved for individual 
genes. Related to this it must be realized that reliable detection of mutations or splice variants depends on the effi-
cacy of smMIPs covering the area of interest. This may present a problem when trying to detect mutations in VHL 
using smMIPs 1,8 or 10. A way of improvement could be to rebalance the smMIP concentrations in the capture 
pool for smMIPs having low capture efficiency. With the generation of a database containing targeted RNAseq 
datasets from large numbers of cancers with the same smMIP panel it will become possible in the future to assign 
a value of relevance to individual smMIPs.
Targeting of cancer-specific metabolic pathways is gaining importance in cancer research. Since decades gly-
colysis has been considered the predominant metabolic pathway in cancer, but it is increasingly clear that tumors 
can also thrive on other sources, such as amino acids, acetate and fatty acids. Identification of the fuel-processing 
pathways that represent metabolic Achilles heels in cancer is important to apply metabolic inhibitors in a personal-
ized fashion. SmMIP-based transcript profiling may be a highly relevant alternative with added value in the field of 
cancer diagnostics as it can identify metabolic Achilles heels by simultaneously measuring relative gene expression 
levels and detecting variants. When combined with smMIP sets that detect actionable mutations in oncogenes or 
tumor suppressor genes, personalized treatment protocols may be optimized by including inhibitors of the most pre-
dominant metabolic pathways (e.g. 3-bromopyruvate, dichloroacetate for glycolysis53–55, 6-aminonicotinamide for 
the pentose phosphate pathway20, epigallocathechin-3-gallate for glutaminolysis56, 57, metformin for mitochondrial 
oxidative phosphorylation58–60), cerulenin for fatty acid oxidation and lipid synthesis61).
Materials and Methods
Cell lines. The cell line SKRC7 is derived from a primary human ccRCC and has been described before46. 
Cells were cultured in RPMI 1640 (Lonza Group, Switzerland) supplemented with 10% fetal calf serum (FCS) 
(Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and 40 µg/ml gentamycin (Centrafarm, Etten-Leur, The 
Figure 5. smMIP-based targeted RNA next generation sequencing can be used for adequate variant calling. 
Shown are the loci containing the IDH1-R132H mutation in E478 xenografts (a) and in a clinical grade III 
astrocytoma (c), this mutation was confirmed by genetic analysis), whereas the IDH1-R314C mutation in E98 
cells could also be identified (b).
www.nature.com/scientificreports/
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Netherlands). An isogenic SKRC7 cell line expressing a functional haemagglutinine (HA)-tagged VHL (SKRC7-
VHLHA) was created by transfection with pcDNA3.1-VHLHA followed by selection of stable transfectants in the 
same medium with 400 µg/ml geneticin (Gibco, Thermo Fisher Scientific, Waltham, MA, USA). The patient-de-
rived glioma xenograft models E478 and E98 have been described before48, 62.
Patient material. Use of patient material for this study was approved by the local ethical committee of 
Radboudumc, and involved prior informed consent. All methods were performed in accordance with the guide-
lines for use of human tissue of the Radboudumc. Tissue was analyzed in a to the researcher team anonymized 
manner. Surgically obtained tissue from a patient with a grade III astrocytoma was snap frozen in liquid nitrogen. 
From four patients suspected for clear cell renal cell cancer, tissue was collected shortly after tumor nephrectomy 
and snap frozen.
RNA and cDNA preparation. Total RNA was isolated from sections of snap-frozen E478 xenograft tis-
sue, human tumor tissues and from 80% confluent SKRC7 and SKRC7-VHLHA cells using TRIzol reagent (Life 
Technologies, ThermoFisher Scientific, Waltham, MA, USA) according to the manufacturers’ instructions. 
RNA quality was estimated based on relative levels of 28S, 18S and 5S rRNA bands on agarose gel and with 
Bioanalyzer assays (Agilent Technologies, Amstelveen, The Netherlands). RNA was reverse transcribed to cDNA 
using Superscript II reverse transcriptase (Invitrogen, ThermoFisher Scientific, Waltham, MA, USA) and ran-
dom hexamer primers (Promega, Madison, WI, USA) according to standard protocols. Next, cDNA was purified 
using the NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel, Düren, Germany). For quality control, cDNA 
was subjected to PCR for reference gene hydroxymethylbilane Synthase (HBMS) with forward primer HMBSFw 
(5′-CTGGTAACGGCAATGCGGCT-3′) and reverse primer HMBSRv (5′-TTCTTCTCCAGGGCATGTTC-3′) 
using AmpliTaq Gold 360 master mix (Applied Biosystems, ThermoFisher Scientific, Waltham, MA USA).
Whole transcriptome RNAseq analysis. High quality RNA with RIN scores >8 was subjected to whole 
transcriptome RNAseq at the genomics core facility of the Netherlands Cancer Institute according to standard 
protocols. Sequencing was performed on an Illumina Hiseq and yielded 30–50 million reads per sample (paired 
end sequencing protocol). The dataset was analyzed using the ‘Tuxedo’ protocol; reads were mapped against the 
RefSeq human genome (GRCh37.55) with TopHat and final transcript assembly was done with the Cufflinks 
package63. FeatureCount was used on the BAM files to extract gene counts which were then transformed to 
transcript per million mapped reads (TPM) to obtain relative expression values. Occurrence of single nucleotide 
variants was visualized in the Integrated Genomics Viewer browser (IGV, the Broadinstitute).
smMIP design. The technique of targeted RNAseq using smMIPs is depicted in Fig. 1. It is based on the hybrid-
ization of an extension and ligation probe, joined by a backbone sequence, in an inverted manner to a cDNA of 
interest, followed by gap-filling/ligation and PCR. SmMIPs against the antisense strand of 104 predicted transcripts 
(UCSC human genome assembly hg19) were designed based on the MIPgen algorithm as described by Boyle et al.64. 
Whenever possible, smMIPs were designed with ligation and extension probes located on adjacent exons to prevent 
contribution of smMIP probes that hybridize to potential contaminations of genomic DNA. Transcripts of interest 
were encoding enzymes and transporters functioning in various metabolic pathways, including lipid metabolism, 
glycolysis, oxidative phosphorylation (OXPHOS), tricarboxylic acid (TCA) cycle, pentose phosphate pathway (PPP), 
glutaminolysis and control of reductive potential (see Table 1). The smMIP set also contained probes for detection of 
β-actin and β-tubulin as housekeeping genes, and a number of tyrosine kinases with relevance for cancer. SmMIPs 
were designed with extension probes of minimum length of 16 nt and ligation probes of minimum length of 18 nt, 
joined by a constant backbone sequence (40 nt) with a stretch of 8 random nucleotides (unique molecule identifier, 
UMI) incorporated adjacent to the ligation probe. The UMI is incorporated to reduce all amplicons originating from 
one individual smMIP to one unique MIP (see below). The length of gap-fill was set at 112 nt. Whereas the design was 
based on full coverage, for the majority of transcripts 5–10 smMIPS per transcript were included in the panel with the 
target regions distributed evenly over the reading frame. For 18 transcripts (CS, D-2HGDH, L-2HGDH, FH, IDH1-
3A-G, MDH1-2, MYC, OGDH, SDHA-D, VHL) smMIP sets were chosen that covered the full coding sequences.
Capture and library preparation. Generation of libraries was performed with a procedure adapted from 
O’Roak et al.65. In short, 642 smMIPs (IDT, Leuven, Belgium) were pooled at 100 µM/smMIP. The smMIP pool 
was phosphorylated using T4 Polynucleotide Kinase (New England Biolabs, NEB, Ipswich, MA, USA) in T4 
DNA ligase buffer (NEB) at 37 °C for 45 min, followed by inactivation for 20 min at 65 °C. The capture reaction 
was performed with 50 ng of cDNA and an estimated 8000-fold molar excess of the phosphorylated smMIP 
pool45 in a 25 μL reaction mixture containing Ampligase buffer (Epicentre, Madison, WI, USA), dNTPs, Hemo 
KlenTaq enzyme (New England Biolabs, NEB, Ipswich, MA, USA) and thermostable DNA ligase (Ampligase, 
Epicentre). The capture mix was incubated for 10 min at 95 °C (denaturation), followed by incubation for 18 h 
at 60 °C, during which hybridization and concomitant primer extension and ligation occurs. Directly after this 
step non-circularized smMIPs, RNA and cDNA were removed by treatment with 10 U Exonuclease I and 50 
U of Exonuclease III (both NEB) for 45 min at 37 °C, followed by heat inactivation (95 °C, 2 min). The circu-
larized smMIP library was subjected to standard PCR with 2x iProof High-Fidelity DNA Polymerase master 
Mix (Bio-Rad, Hercules, CA) with a primer set containing a unique barcoded reverse primer for each sam-
ple. Generation of PCR products of correct size (266 bp) was validated on agarose gel electrophoresis, and 
PCR-libraries from different samples were pooled based on relative band intensity. The pool was then purified 
using AMPureXP beads (Beckman Coulter Genomics, High Wycombe, UK) according to manufacturers’ instruc-
tions. The purified library was run on a TapeStation 2200 (Agilent Technologies, Santa Clara, CA, USA) and 
quantified via Qubit (Life Technologies, ThermoFisher Scientific, Waltham, MA USA) to assess quality of the 
library.
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Reproducibility of the technique was tested by preparing biological replica libraries, using different RNA 
preparations from the same cell lines.
Sequencing and annotation. Libraries were sequenced on the Illumina NextSeq platform (Illumina, San 
Diego, CA) at the Radboudumc sequencing facility to produce 2 × 151 bp paired-end reads. Reads were mapped 
to the reference transcriptome (hg19) using the SeqNext module of JSI SequencePilot version 4.2.2 build 502 (JSI 
Medical Systems, Ettenheim, Germany). The random 8 nt sequence flanking the ligation probe was used to reduce 
PCR amplicates to one smMIP (unique reads).
Single nucleotide variant (SNV) calling and expression analysis. All single nucleotide variants 
(SNVs) called with a minimal variant percentage of 5% detected in at least 5 unique reads (forward and reverse) 
were selected for further analysis. Variants were annotated and classified into synonymous or non-synonymous. 
Next, they were validated in whole transcriptome RNAseq data, generated from different RNA isolations from 
the same cell lines.
Individual read counts for each smMIP were divided by the total read count within a sample and multiplied 
by 106 resulting in a fragment per million (FPM) value for each smMIP in a sample. We choose for this normal-
ization procedure instead of normalization against housekeeping genes because perfect housekeeping genes do 
not exist.
Western blotting. Cell extracts were prepared from SKRC7 and SKRC7-VHLHA cells by solubilizing in RIPA 
buffer (Cell Signaling) and protein concentrations were determined using BCA assays. 20 µg of protein was sepa-
rated on 12% SDS-PAGE gels and electroblotted on nitrocellulose. After blocking in Odyssey blocking buffer (1:1 
in PBS) membranes were incubated overnight in Odyssey blocking buffer containing antibodies against HK-2 
(2867S, Cell signaling technology), CA9 (M75, Dr. Oosterwijk) or γ-tubulin (C20, Santa Cruz Biotechnology, 
Dallas, TX) as loading control. Antibodies were detected with secondary antibodies conjugated with Alexa680 or 
DyLight800, and signal was visualized with the Odyssey scanner (LI-COR).
Statistics. FPM values for each transcript (mean FPM values from all smMIPs targeting one transcript) were 
correlated with TPM values (transcripts per million values for the same transcript obtained from whole RNAseq 
data from the same cell lines. For three samples replicate assays were performed. Correlation analyses were per-
formed using GraphPad Prism v.5.03 (GraphPad, San Diego, CA, USA).
Data availability. Data relating to this manuscript (excel files with FPM values) will be made available to 
researchers upon request.
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